Healthcare stocks rallied in 2025, breaking a two-year slump as investors chased steadier rates, better valuations, and improving earnings. The problem: mid-single-digit gains still lagged tech, leaving the sector feeling like a missed opportunity.
For investors still hunting for healthcare growth, the answer doesn’t have to lie in the high-risk, high-reward world of biotech. Instead of betting on binary clinical-trial outcomes, many are rotating into MedTech and healthcare services—areas built on procedure volume, recurring revenue, and “tools-and-infrastructure” demand that can scale without the same make-or-break drug risk.
